

# Hovav Nechushtan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8814138/publications.pdf>

Version: 2024-02-01

71  
papers

3,271  
citations

218677

26  
h-index

149698

56  
g-index

72  
all docs

72  
docs citations

72  
times ranked

5153  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer. <i>Nature Cancer</i> , 2022, 3, 219-231.	13.2	24
2	dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score $\geq 50\%$ . <i>Clinical Lung Cancer</i> , 2022, 23, 122-134.	2.6	8
3	Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study. <i>Neuro-Oncology Advances</i> , 2022, 4, vdab188.	0.7	9
4	FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC). <i>Journal of Clinical Medicine</i> , 2022, 11, 2475.	2.4	8
5	Long term follow-up of EGFR mutated NSCLC cases. <i>Translational Oncology</i> , 2021, 14, 100934.	3.7	6
6	Differential functions of TLE1 and TLE3 depending on a specific phosphorylation site. <i>Biochemical and Biophysical Research Communications</i> , 2021, 545, 164-170.	2.1	1
7	SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1- $\beta$ , and Point Mutation in the Transcription Intermediary Factor 1- $\beta$ Coding Gene: A Case Report. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100217.	1.1	3
8	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) $\geq 50\%$ : real-world data. <i>Oncolmmunology</i> , 2021, 10, 1865653.	4.6	24
9	Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa125.	0.7	12
10	Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis. <i>FASEB Journal</i> , 2020, 34, 4204-4218.	0.5	70
11	Ap4A Regulates Directional Mobility and Antigen Presentation in Dendritic Cells. <i>IScience</i> , 2019, 16, 524-534.	4.1	3
12	Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization. <i>Lung Cancer</i> , 2019, 137, 48-51.	2.0	22
13	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). <i>Oncologist</i> , 2019, 24, 491-497.	3.7	22
14	BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1128-1137.	1.1	160
15	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation—Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1897-1905.	1.1	68
16	There must be another way—disulfiram and cancer treatment: editorial on “Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4”. <i>Translational Cancer Research</i> , 2018, 7, S491-S494.	1.0	1
17	RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients. <i>Clinical Lung Cancer</i> , 2017, 18, e223-e232.	2.6	24
18	PET/CT With $^{68}\text{Ga}$ -DOTA-TATE for Diagnosis of Neuroendocrine. <i>Clinical Nuclear Medicine</i> , 2017, 42, 1-6.	1.3	60

#	ARTICLE	IF	CITATIONS
19	Serine 207 phosphorylated lysyl-tRNA synthetase predicts disease-free survival of non-small-cell lung carcinoma. <i>Oncotarget</i> , 2017, 8, 65186-65198.	1.8	9
20	Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 305-312.	2.5	37
21	New ARCHITECT plasma pro-gastrin-releasing peptide assay for diagnosing and monitoring small-cell lung cancer. <i>British Journal of Cancer</i> , 2016, 114, 469-476.	6.4	18
22	Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver. <i>Anticancer Research</i> , 2016, 36, 1791-7.	1.1	6
23	FHL2 switches MITF from activator to repressor of Erbin expression during cardiac hypertrophy. <i>International Journal of Cardiology</i> , 2015, 195, 85-94.	1.7	15
24	A Phase IIb Trial Assessing the Addition of Disulfiram to Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2015, 20, 366-367.	3.7	158
25	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 14139-14152.	1.8	22
26	EGFR Mutation Testing Practice in Advanced Non-Small Cell Lung Cancer. <i>Lung</i> , 2014, 192, 759-763.	3.3	5
27	A phase 1/2 of a combination of Cetuximab and Taxane for triple negative breast cancer patients. <i>Breast</i> , 2014, 23, 435-438.	2.2	23
28	Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients: A Brief Report. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1568-1572.	1.1	24
29	Structural Switch of Lysyl-tRNA Synthetase between Translation and Transcription. <i>Molecular Cell</i> , 2013, 49, 30-42.	9.7	131
30	Amino-Acyl tRNA Synthetases Generate Dinucleotide Polyphosphates as Second Messengers: Functional Implications. <i>Topics in Current Chemistry</i> , 2013, 344, 189-206.	4.0	21
31	Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 407-413.	2.5	30
32	EGFR mutation in lung cancer: tumor heterogeneity and the impact of chemotherapy. <i>Chinese Clinical Oncology</i> , 2013, 2, 2.	1.2	16
33	Mast cell transcription factors—Regulators of cell fate and phenotype. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 42-48.	3.8	27
34	Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. <i>Nature Medicine</i> , 2012, 18, 382-384.	30.7	782
35	Importin Beta Plays an Essential Role in the Regulation of the LysRS-Ap <sup>4</sup> A Pathway in Immunologically Activated Mast Cells. <i>Molecular and Cellular Biology</i> , 2011, 31, 2111-2121.	2.3	16
36	Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. <i>Blood</i> , 2010, 115, 570-580.	1.4	73

#	ARTICLE	IF	CITATIONS
37	The complexity of the complicity of mast cells in cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 551-554.	2.8	37
38	A Specific Epitope of Protein Inhibitor of Activated STAT3 Is Responsible for the Induction of Apoptosis in Rat Transformed Mast Cells. <i>Journal of Immunology</i> , 2009, 182, 2168-2175.	0.8	18
39	Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations. <i>BMC Cancer</i> , 2009, 9, 60.	2.6	10
40	Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immunochemotherapy. <i>British Journal of Haematology</i> , 2009, 147, 308-318.	2.5	10
41	LysRS Serves as a Key Signaling Molecule in the Immune Response by Regulating Gene Expression. <i>Molecular Cell</i> , 2009, 34, 603-611.	9.7	148
42	Chapter 1 The Physiological Role of Lysyl tRNA Synthetase in the Immune System. <i>Advances in Immunology</i> , 2009, 103, 1-27.	2.2	23
43	Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 663-675.	4.2	3
44	Mast cells and cancer—No longer just basic science. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, 115-130.	4.4	75
45	Diadenosine Tetrphosphate Hydrolase Is Part of the Transcriptional Regulation Network in Immunologically Activated Mast Cells. <i>Molecular and Cellular Biology</i> , 2008, 28, 5777-5784.	2.3	41
46	Interleukin-21 Induces Cell Cycle Arrest and Apoptosis of Diffuse Large B-Cell Lymphomas (DLBCL) Via Activation of STAT3 and Upregulation of C-Myc. <i>Blood</i> , 2008, 112, 601-601.	1.4	2
47	Microphthalmia Transcription Factor Isoforms in Mast Cells and the Heart. <i>Molecular and Cellular Biology</i> , 2007, 27, 3911-3919.	2.3	25
48	Adoptively Transferred Tumor-Specific T Cells Stimulated <i>Ex vivo</i> Using Herpes Simplex Virus Amplicons Encoding 4-1BBL Persist in the Host and Show Antitumor Activity <i>In vivo</i> . <i>Cancer Research</i> , 2007, 67, 10027-10037.	0.9	17
49	Identifying a common molecular mechanism for inhibition of MITF and STAT3 by PIAS3. <i>Blood</i> , 2006, 107, 2839-2845.	1.4	26
50	Mast cells: must they always be different?. <i>Blood</i> , 2006, 107, 1-2.	1.4	7
51	Translocation of Active Heparanase to Cell Surface Regulates Degradation of Extracellular Matrix Heparan Sulfate upon Transmigration of Mature Monocyte-Derived Dendritic Cells. <i>Journal of Immunology</i> , 2006, 176, 6417-6424.	0.8	51
52	Interleukin-21-Induced Apoptosis and Cell Death of Diffuse Large B-Cell Lymphoma (DLBCL) Cell Lines and Primary Tumors Are Associated with an Induction of Bim.. <i>Blood</i> , 2006, 108, 2503-2503.	1.4	2
53	Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. <i>Blood</i> , 2005, 105, 2924-2932.	1.4	63
54	Rituximab Mediated Depletion of B Cells Following Transplant of Human CD20 Transgenic Mouse Bone Marrow Results in Prolonged B Cell Depletion and Augmented Anti-Tumor Immune Response.. <i>Blood</i> , 2005, 106, 2205-2205.	1.4	0

#	ARTICLE	IF	CITATIONS
55	c-Fos as a Regulator of Degranulation and Cytokine Production in Fc̳RI-Activated Mast Cells. <i>Journal of Immunology</i> , 2004, 173, 2571-2577.	0.8	59
56	The Function of Lysyl-tRNA Synthetase and Ap4A as Signaling Regulators of MITF Activity in Fc̳RI-Activated Mast Cells. <i>Immunity</i> , 2004, 20, 145-151.	14.3	161
57	IL-4 Affects Proliferation, Chemosensitivity-and Rituximab Sensitivity of Germinal Center B-Cell like (GCB) and Activated B-Cell like (ABC) Diffuse Large B-Cell Lymphoma Differently.. <i>Blood</i> , 2004, 104, 242-242.	1.4	4
58	Distinct IL-4 Intracellular Signaling in Germinal Center B-Cell like and Activated B-Cell like Diffuse Large B-Cell Lymphoma: Novel Opportunities for Therapeutic Interventions.. <i>Blood</i> , 2004, 104, 244-244.	1.4	1
59	A novel strategy using single-chain antibody to show the importance of Bcl-2 in mast cell survival. <i>Blood</i> , 2003, 102, 2506-2512.	1.4	36
60	A New Role for the STAT3 Inhibitor, PIAS3. <i>Journal of Biological Chemistry</i> , 2002, 277, 1962-1966.	3.4	81
61	The function of MITF and associated proteins in mast cells. <i>Molecular Immunology</i> , 2002, 38, 1177-1180.	2.2	32
62	Studies of Different Aspects of the Role of Protein Kinase C in Mast Cells. <i>International Archives of Allergy and Immunology</i> , 2001, 124, 130-132.	2.1	11
63	Inhibition of degranulation and interleukin-6 production in mast cells derived from mice deficient in protein kinase C̳2. <i>Blood</i> , 2000, 95, 1752-1757.	1.4	118
64	Suppression of Microphthalmia Transcriptional Activity by Its Association with Protein Kinase C-interacting Protein 1 in Mast Cells. <i>Journal of Biological Chemistry</i> , 1999, 274, 34272-34276.	3.4	92
65	Growth-dependent and PKC-mediated translational regulation of the upstream stimulating factor-2 (USF2) mRNA in hematopoietic cells. <i>Oncogene</i> , 1998, 16, 763-769.	5.9	10
66	Involvement of HNF-1 in the regulation of phosphoenolpyruvate carboxykinase gene expression in the kidney. <i>FEBS Letters</i> , 1997, 412, 597-602.	2.8	32
67	Analysis of cytokine profile in human colonic mucosal Fc̳RI-positive cells by single cell PCR: inhibition of IL-3 expression in steroid-treated IBD patients. <i>FEBS Letters</i> , 1997, 413, 436-440.	2.8	14
68	Microphthalmia (mi) in Murine Mast Cells: Regulation of Its Stimuli-Mediated Expression on the Translational Level. <i>Blood</i> , 1997, 89, 2999-3008.	1.4	27
69	Murine and human mast cell express acetylcholinesterase. <i>FEBS Letters</i> , 1996, 379, 1-6.	2.8	14
70	Regulation of mast cell growth and proliferation. <i>Critical Reviews in Oncology/Hematology</i> , 1996, 23, 131-150.	4.4	11
71	Glucocorticoids control phosphoenolpyruvate carboxykinase gene expression in a tissue specific manner. <i>Nucleic Acids Research</i> , 1987, 15, 6405-6417.	14.5	72